Sector News

Illumina appoints Paula Dowdy to lead commercial operations for EMEA

June 6, 2016
Life sciences

Illumina, Inc. today announced that it has appointed Paula Dowdy to lead the Europe, Middle East and Africa (EMEA) commercial team as Senior Vice President and General Manager.

Paula was previously Senior Vice President for Cloud, Software, and Managed Services at Cisco.

“We are truly excited for Paula to lead our EMEA commercial operations team,” said Christian Henry, Executive Vice President for Commercial Operations. “Paula brings a proven track record of leadership, insight and execution, and her passion for delivering customer success will serve the EMEA region exceptionally well. Additionally, this hire supports our strategy to bring in expertise from large-scale companies to complement our leadership team.”

Paula joined Cisco 20 years ago and has spent the majority of her career in Europe. She has held numerous senior positions leading Cisco product and services groups for virtually all customer segments. In her most recent role, Paula led Cisco’s go-to-market team for Cloud, Software, and Managed Services where she drove the incubation of innovative new solutions.

Paula holds an MBA degree from Pepperdine University and a Bachelor of Arts degree from the University of California, Berkeley. Paula will officially join Illumina August 1, 2016.

Source: Illumina

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend